HTI Vaccine Immune Response Assessment for ART Interruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV are lengthy, costly, and prone to adverse effects, with challenges in adherence and resistance, necessitating a method to assess immune response to HIVACAT T-cell immunogen (HTI) for personalized treatment decisions.
Innovation Solution
Administering HTI immunogen to subjects, evaluating their immune response, and adjusting antiretroviral therapy based on the magnitude of this response to optimize treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiretroviral therapy is administered to control HIV, then viral suppression is achieved, but treatment duration extends to lifetime with associated adverse effects and costs
Solution Approach 1:
The vaccine is administered before initiating antiretroviral therapy to establish protective immune memory in advance. This preliminary immunization allows the immune system to be primed with HIV-specific T-cell responses, enabling potential treatment interruption or reduced duration while maintaining viral suppression
Solution Approach 2:
The method incorporates assessment of immune response magnitude to the HTI immunogen as a feedback mechanism. By measuring T-cell responses and using this information to guide treatment decisions, the therapy duration can be optimized based on individual immune status rather than following fixed lifetime treatment protocols
2Reliability
If combination antiretroviral therapy is used to achieve effective HIV control, then viral load is suppressed, but adherence fatigue and resistance development occur
Solution Approach 1:
The immune response assessment provides objective feedback that can motivate patients by demonstrating their immune system's protective capacity. This tangible measure of immune protection may improve adherence by reducing adherence fatigue and enhancing patient engagement in treatment
Solution Approach 2:
By establishing immune protection through vaccination before therapy initiation, the burden of lifelong adherence is potentially reduced. The preliminary immune priming creates a foundation that may allow for simplified or interrupted therapy regimens, thereby improving long-term adherence
3Reliability
If lifelong antiretroviral therapy is provided to ensure continuous HIV control, then health outcomes improve, but costs to patients and health systems increase significantly
Solution Approach 1:
The immune response magnitude assessment serves as a cost-saving feedback mechanism by identifying patients who have developed sufficient protective immunity. This allows for potential treatment interruption or reduction in high-cost antiretroviral medications, thereby reducing overall treatment costs while maintaining HIV control in responsive individuals
Solution Approach 2:
The method changes the parameter of treatment duration from fixed (lifetime) to variable (based on immune response). By adjusting treatment parameters according to individual immune status, unnecessary long-term medication costs are avoided for patients who can maintain control through vaccine-induced immunity alone
Data Source
AI summary
The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and/or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.